477 related articles for article (PubMed ID: 33185650)
1. Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial.
Lam CSP; Giczewska A; Sliwa K; Edelmann F; Refsgaard J; Bocchi E; Ezekowitz JA; Hernandez AF; O'Connor CM; Roessig L; Patel MJ; Pieske B; Anstrom KJ; Armstrong PW;
JAMA Cardiol; 2021 Jun; 6(6):706-712. PubMed ID: 33185650
[TBL] [Abstract][Full Text] [Related]
2. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study.
Ezekowitz JA; O'Connor CM; Troughton RW; Alemayehu WG; Westerhout CM; Voors AA; Butler J; Lam CSP; Ponikowski P; Emdin M; Patel MJ; Pieske B; Roessig L; Hernandez AF; Armstrong PW
JACC Heart Fail; 2020 Nov; 8(11):931-939. PubMed ID: 33039447
[TBL] [Abstract][Full Text] [Related]
3. Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial.
Lam CSP; Mulder H; Lopatin Y; Vazquez-Tanus JB; Siu D; Ezekowitz J; Pieske B; O'Connor CM; Roessig L; Patel MJ; Anstrom KJ; Hernandez AF; Armstrong PW;
J Am Heart Assoc; 2021 Nov; 10(22):e021094. PubMed ID: 34743540
[TBL] [Abstract][Full Text] [Related]
4. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.
Gheorghiade M; Greene SJ; Butler J; Filippatos G; Lam CS; Maggioni AP; Ponikowski P; Shah SJ; Solomon SD; Kraigher-Krainer E; Samano ET; Müller K; Roessig L; Pieske B;
JAMA; 2015 Dec; 314(21):2251-62. PubMed ID: 26547357
[TBL] [Abstract][Full Text] [Related]
5. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
Armstrong PW; Pieske B; Anstrom KJ; Ezekowitz J; Hernandez AF; Butler J; Lam CSP; Ponikowski P; Voors AA; Jia G; McNulty SE; Patel MJ; Roessig L; Koglin J; O'Connor CM;
N Engl J Med; 2020 May; 382(20):1883-1893. PubMed ID: 32222134
[TBL] [Abstract][Full Text] [Related]
6. Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction.
Mentz RJ; Stebbins A; Butler J; Chiang CE; Ezekowitz JA; Hernandez AF; Hilkert R; Lam CSP; McDonald K; O'Connor CM; Pieske B; Ponikowski P; Roessig L; Sweitzer NK; Voors AA; Anstrom KJ; Armstrong PW;
JACC Heart Fail; 2024 May; 12(5):839-846. PubMed ID: 38363272
[TBL] [Abstract][Full Text] [Related]
7. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.
Armstrong PW; Lam CSP; Anstrom KJ; Ezekowitz J; Hernandez AF; O'Connor CM; Pieske B; Ponikowski P; Shah SJ; Solomon SD; Voors AA; She L; Vlajnic V; Carvalho F; Bamber L; Blaustein RO; Roessig L; Butler J;
JAMA; 2020 Oct; 324(15):1512-1521. PubMed ID: 33079152
[TBL] [Abstract][Full Text] [Related]
8. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial.
Pieske B; Patel MJ; Westerhout CM; Anstrom KJ; Butler J; Ezekowitz J; Hernandez AF; Koglin J; Lam CSP; Ponikowski P; Roessig L; Voors AA; O'Connor CM; Armstrong PW;
Eur J Heart Fail; 2019 Dec; 21(12):1596-1604. PubMed ID: 31820546
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial.
Chew DS; Li Y; Bigelow R; Cowper PA; Anstrom KJ; Daniels MR; Davidson-Ray L; Hernandez AF; O'Connor CM; Armstrong PW; Mark DB;
Circulation; 2023 Oct; 148(14):1087-1098. PubMed ID: 37671551
[TBL] [Abstract][Full Text] [Related]
10. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
Armstrong PW; Roessig L; Patel MJ; Anstrom KJ; Butler J; Voors AA; Lam CSP; Ponikowski P; Temple T; Pieske B; Ezekowitz J; Hernandez AF; Koglin J; O'Connor CM
JACC Heart Fail; 2018 Feb; 6(2):96-104. PubMed ID: 29032136
[TBL] [Abstract][Full Text] [Related]
11. Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat.
Coats AJS; Tolppanen H
Drugs; 2021 Sep; 81(14):1599-1604. PubMed ID: 34478114
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial.
Senni M; Alemayehu WG; Sim D; Edelmann F; Butler J; Ezekowitz J; Hernandez AF; Lam CSP; O'Connor CM; Pieske B; Ponikowski P; Roessig L; Voors AA; Westerhout CM; McMullan C; Armstrong PW;
Eur J Heart Fail; 2022 Sep; 24(9):1614-1622. PubMed ID: 35791083
[TBL] [Abstract][Full Text] [Related]
13. Classification of Heart Failure Events by Severity: Insights From the VICTORIA Trial.
Felker GM; North R; Mulder H; Jones WS; Anstrom KJ; Patel MJ; Butler J; Ezekowitz JA; Lam CSP; O'Connor CM; Roessig L; Hernandez AF; Armstrong PW;
J Card Fail; 2023 Aug; 29(8):1113-1120. PubMed ID: 37331690
[TBL] [Abstract][Full Text] [Related]
14. Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA.
Butler J; Zheng Y; Khan MS; Bonderman D; Lund LH; deFilippi CR; Blaustein RO; Ezekowitz JA; Freitas C; Hernandez AF; O'Connor CM; Voors AA; Westerhout CM; Lam CSP; Armstrong PW;
JACC Heart Fail; 2023 May; 11(5):583-592. PubMed ID: 37137660
[TBL] [Abstract][Full Text] [Related]
15. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
Pieske B; Maggioni AP; Lam CSP; Pieske-Kraigher E; Filippatos G; Butler J; Ponikowski P; Shah SJ; Solomon SD; Scalise AV; Mueller K; Roessig L; Gheorghiade M
Eur Heart J; 2017 Apr; 38(15):1119-1127. PubMed ID: 28369340
[TBL] [Abstract][Full Text] [Related]
16. Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial.
Ponikowski P; Alemayehu W; Oto A; Bahit MC; Noori E; Patel MJ; Butler J; Ezekowitz JA; Hernandez AF; Lam CSP; O'Connor CM; Pieske B; Roessig L; Voors AA; Westerhout C; Armstrong PW;
Eur J Heart Fail; 2021 Aug; 23(8):1300-1312. PubMed ID: 34191395
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology of Worsening Heart Failure in a Population-based Cohort from Alberta, Canada: Evaluating Eligibility for Treatment With Vericiguat.
Sepehrvand N; Islam S; Dover DC; Kaul P; McAlister FA; Armstrong PW; Ezekowitz JA
J Card Fail; 2022 Aug; 28(8):1298-1308. PubMed ID: 35589087
[TBL] [Abstract][Full Text] [Related]
18. Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status: Insights From the VICTORIA Trial.
Khan MS; Butler J; Young R; Lewis BS; Escobedo J; Refsgaard J; Reyes E; Roessig L; Blaustein RO; Lam CSP; Voors AA; Ponikowski P; Anstrom KJ; Armstrong PW;
JACC Heart Fail; 2024 Jun; ():. PubMed ID: 38934967
[TBL] [Abstract][Full Text] [Related]
19. Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction.
Saldarriaga C; Atar D; Stebbins A; Lewis BS; Abidin IZ; Blaustein RO; Butler J; Ezekowitz JA; Hernandez AF; Lam CSP; O'Connor CM; Pieske B; Ponikowski P; Roessig L; Voors AA; Anstrom KJ; Armstrong PW;
Eur J Heart Fail; 2022 May; 24(5):782-790. PubMed ID: 35239245
[TBL] [Abstract][Full Text] [Related]
20. Vericiguat: A Review in Chronic Heart Failure with Reduced Ejection Fraction.
Kang C; Lamb YN
Am J Cardiovasc Drugs; 2022 Jul; 22(4):451-459. PubMed ID: 35624347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
